Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

NewsGuard 100/100 Score

Forest Laboratories, Inc. (NYSE: FRX) and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations. Included in the poster presentations are additional results from the 12-month and 6-month roflumilast studies previously published in The Lancet.

The scheduled times and titles of presentations are:

  • Roflumilast and its active metabolite inhibit LPS-induced cytokine production from human lung macrophages by a PGE2-dependent mechanism: poster (D7) available on Sunday, May 16, 8:15 am - 4:00 pm CDT, with presentation by A. Buenestado, PhD, 10:45 am - 12:30 pm
  • Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months: poster (F72) available on Tuesday, May 18, 8:15 am - 4:00 pm CDT, with presentation by N.A. Hanania, MD, MS, 10:45 am - 12:30 pm
  • Time course and reversibility of weight decrease with roflumilast, a PDE4 inhibitor: poster (F78) available on Tuesday, May 18, 8:15 am - 4:00 pm CDT, with presentation by F.J. Martinez, MD, MS, 10:45 am - 12:30 pm
  • Effects of roflumilast, a PDE4 inhibitor, on body composition in chronic obstructive pulmonary disease: poster (B64) available on Tuesday, May 18, 8:15 am - 4:00 pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am - 12:30 pm
  • Effects of roflumilast, a PDE4 inhibitor, on glucose homeostasis in patients with treatment-naïve diabetes: poster (B62) available on Tuesday, May 18, 8:15 am - 4:00 pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am - 12:30 pm
  • Roflumilast N-oxide partially prevents the loss of ciliated human airway epithelial cells secondary to incubation with cigarette smoke extracts in vitro: poster (B68) available on Tuesday, May 18, 8:15 am - 4:00 pm CDT, with presentation by J. Milara, PhD, 10:45 am - 12:30 pm
Source:

 Forest Laboratories

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hydrogel with built-in antibiofilm and antioxidative functions promotes faster healing of infected chronic wounds